Genmab A/S (NASDAQ:GMAB – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.
Insider & Institutional Ownership
7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genmab A/S | 0 | 3 | 9 | 1 | 2.85 |
| Whitehawk Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
Genmab A/S currently has a consensus target price of $39.50, suggesting a potential upside of 21.65%. Whitehawk Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 99.51%. Given Whitehawk Therapeutics’ higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Genmab A/S.
Profitability
This table compares Genmab A/S and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genmab A/S | 19.08% | 14.89% | 7.73% |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
Valuation & Earnings
This table compares Genmab A/S and Whitehawk Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genmab A/S | $4.13 billion | 4.90 | $963.00 million | $1.27 | 25.57 |
| Whitehawk Therapeutics | $7.14 million | 32.82 | -$20.60 million | ($1.12) | -3.67 |
Genmab A/S has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Genmab A/S beats Whitehawk Therapeutics on 11 of the 15 factors compared between the two stocks.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
